Need help?

Biotechnology Business Investment Opportunities

Showing 1 - 14 of 30 Biotechnology Business Investment Opportunities. Invest in a Biotechnology, Agricultural Biotechnology, Biotech Facility, Biopharma, Bio Diagnostic, Bio Medical Device or a Bio Therapeutic Drug Business.

Filters
  • Biotechnology

  • Investment Opportunities

 

Newly Established Biotechnology Company Investment Opportunity in Haverhill, United States

Non-operational business offering CRO services and therapeutic protein distribution seeking funds to kick-start operations.
The company is strategically positioned in the biotechnology sector, with plans to specialize in high-demand services such as flow cytometry and cell culture, tailored to support pharmaceutical, biotech, and diagnostic companies. - Despite being registered 4 years ago, the company has yet to start operations but has laid the groundwork through strategic collaborations and grant submissions totalling approximately USD 40 million, showcasing a strong potential for funding acquisition. - The promoter's extensive background, with a PhD in cell biology and two decades of research experience, provides a strong foundation for the company's technical expertise and leadership. - Possession of distribution rights for crucial research kits and therapeutic proteins indicates early-stage readiness to supply essential products to the research community. - The company maintains strategic collaborations with antibody-based firms, enhancing its capability to provide comprehensive solutions for advanced therapeutic and research needs. - Haverhill, the company's location, provides access to a strategic geographical position that can facilitate partnerships with key biotech and pharmaceutical players. - The planned service offerings, including advanced flow cytometry and specialized cell culture services, underscore the company's commitment to supporting cutting-edge research with reliable and customizable solutions.
7.3   Haverhill
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 1 Mn for 10%
Contact Business

Newly Established Bio Therapeutic Drugs Company Investment Opportunity in Monaragala, Sri Lanka

Ayurvedic doctor with 30+ years of experience needs a foreign investor for cannabis plantation.
Planning to establish a cannabis plantation to produce anesthetic drugs. - Seeking foreign investors to comply with the local law, which mandates that only foreigners can hold a license for cannabis plantations. - The promoter is an Ayurvedic doctor with 30 years of experience in the industry. - We will be applying for licenses, and only foreigners are eligible to hold them. - Our plan is to establish a cannabis plantation and export cannabis anesthetic drugs through distributors worldwide. - The drugs will be specifically formulated for anesthesia purposes.
6.2   Monaragala
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 5 Mn for 40%
Contact Business

Bio Diagnostics Company Investment Opportunity in Singapore

Med-tech R&D company with a patented technology for early stage multi-cancer detection seeks investors.
The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.
Med-tech R&D company with a patented technology for early stage multi-cancer detection seeks investors.
7.8   Singapore
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 14.8 Mn for 10%
Contact Business
List your business on SMERGERS.
Get visibility from 110,000+ member network of Businesses, Investors, Acquirers, Lenders and Advisors from 900+ Industries and 170+ Countries
Create Business Profile

Bio Diagnostics Company Investment Opportunity in Singapore

Med-tech R&D company with a patented technology for early stage multi-cancer detection seeks investors.
The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.
Med-tech R&D company with a patented technology for early stage multi-cancer detection seeks investors.
7.8   Singapore
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 14.8 Mn for 10%
Contact Business

Newly Established Biotechnology Company Investment Opportunity in Brussels, Belgium

AI-enhanced physics-based drug discovery company with diverse clientele, seeking investment for R&D activities in pipeline.
An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.
6.8   Brussels
Run Rate Sales
USD 127 thousand
EBITDA Margin
Nil
Partial Stake Sale
USD 530 K for 25%
Contact Business

Newly Established Bio Therapeutic Drugs Business Investment Opportunity in Sincelejo, Colombia

Patented beverage for acute alcohol intoxication in talks with 18 clients to launch in Columbia.
High potential company with a science-proven, patented beverage for acute alcohol intoxication. - Our product is a science-based beverage designed for the resolution of acute alcohol toxicity. - The company has developed this product over the past 3 years and is now seeking early-stage investors to bring it to market. - We are in discussions with approximately 18 major clients in the pharmaceutical industry, including pharma product buyers and large pharmacies such as Audifarma and Eticos Serrano, to ensure effective product introduction and distribution. - Our team has over 4 years of successful experience in launching pharmaceutical products in the Colombian market. - We will be available in the market in the next few months. - Our target audience is the alcohol consumption market, focusing on providing a solution for alcohol elimination in intoxicated individuals. - The company is currently in the pre-seed stage. - We are planning to establish a manufacturing unit soon, with a production capacity of 100,000 units per month. - Company has incorporation license and INVIMA registration (license from the National Food and Drug Surveillance Institute)
5.7   Sincelejo
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 39 K for 10%
Contact Business

Bio Therapeutic Drugs Company Investment Opportunity in Cambridge, United Kingdom

Drug discovery company with novel drug compounds under trial and a robust R&D infrastructure.
The company is a pharmaceutical and healthcare business based in Cambridge, specializing in drug discovery and development of novel drug compounds. - The company has a small team of 5 employees, with promoters who have over two decades of experience in pharmacology, having worked as scientists at renowned universities in the United Kingdom. - The company's research and development infrastructure is well-established, and it also offers managed print services and contract research in addition to drug development. - The focus of the company's research is on finding a cure for Parkinson's disease, with over 130 tests conducted on the drug compound showing a 75% success rate, with an expected increase to over 90% within the next 2 years. - Upon launch to the public, the company anticipates generating over 90% in profits. - The company's drug discovery and development process is supported by Indian scholar scientists based in the UK, adding a diverse and skilled team to its research efforts. - All research documents related to the drug compounds and trials are available for review, providing transparency and insight into the company's research and development activities.
7.8   Cambridge
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 10.4 Mn for 30%
Contact Business

Bio Medical Devices Company Investment Opportunity in Mumbai, India

Bio-medical startup seeking investment to scale marketing, distribution, and assembly.
The company is a bio-medical startup based in Mumbai with a current manufacturing capacity of 20,000 units and is seeking investment to scale marketing, distribution, and assembly. - The heart rate monitor is the top-selling product, with an average of 200 units sold per month through online channels such as the company's website and Amazon. Revenue sources are diversified, with 40% of sales revenue coming from Amazon and 60% from the company's website. The company utilizes Ship Rocket and Amazon for logistics. - The company's current sales are entirely business-to-consumer (B2C) - The company has garnered interest from Bridge Health and Fitterfly for the use of its product in BP reduction programs, showcasing the potential for further B2B partnerships. - The heart rate monitor is currently sold at an introductory price of INR 1,999 for the first 1,000 devices, with the regular price set at INR 3,499. The company aims to sell approximately 1 lakh units by the end of the year. - The product current has a +/- 2 points tolerance, which shows they are 98% accurate. - Collaborating with telemedicine doctors. - The company has currently outsourced manufacturing with a manufacturing capacity of approximately 20,000 units manufactured a month and we have our own testing and assembly rigs to avoid any leaking of design and work. - The business already has a ready stock of more than 10,000 units in inventory and is sending them for testing to its partners. - The business holds the necessary GST certificate & an ISO 13485 certificate.
8.1   Mumbai
Run Rate Sales
USD 57 thousand
EBITDA Margin
25 %
Partial Stake Sale
USD 590 K for 35%
Contact Business

Bio Therapeutic Drugs Company Investment Opportunity in Milan, Italy

Biotech firm focused on cancer immuno personalized therapy and exosomes for medical and cosmetic applications.
A biotech firm based in Milan, focusing on cancer immuno personalized therapy. - Has a portfolio of R&D projects and two Finished Dosage Forms (FDF) in the Italian market, including Aripiprazole and Emtricitabine + Tenofovir. - The company specializes in the development of microfluidic technology for the production and purification of Exosomes, with applications in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments. - Exosomes, a key product of the company, are body-identical ingredients known for their high stability and low likelihood of causing adverse reactions. Their cell-penetrating mechanism enables them to deliver regeneration signals, making them suitable for diverse medical and cosmetic applications. - Has 3 major clients and supplied on a quarterly basis to pharmaceutical companies in Italy, Poland, and Brazil. - Operates with a network of 12 agents in addition to its 3 permanent employees. - Collaborates with Contract Manufacturing Organizations (CMOs) for the production of its pharmaceutical products. The company holds essential regulatory licenses from GMP, FDA, and the Ministry of Health, ensuring compliance with international quality and safety standards.
8.1   Milan
Run Rate Sales
USD 320 thousand
EBITDA Margin
35 %
Partial Stake Sale
USD 1.6 Mn for 25%
Contact Business

Biotechnology Company Investment Opportunity in Mexico City, Mexico

Research and development of genetic excellence in seeds for professional vegetable growers.
R+D and distribution of vegetable seeds. - Exclusivity of highest yielding Roma tomato variety that will change the 12,000 hectares market in Mexico for the next 4-8 years with a potential revenue of US$20-30M per year only for this variety alone. - Great network of suppliers and clients. - There are 20 permanent employees. No additional contract/temporary employees.
Research and development of genetic excellence in seeds for professional vegetable growers.
8.9   Mexico City
Run Rate Sales
USD 8.4 million
EBITDA Margin
10 - 20 %
Partial Stake Sale
USD 3.7 Mn for 40%
Contact Business

Bio Diagnostics Business Investment Opportunity in Manlius, United States

We develop diagnostics, therapeutics, & digital health products and services for skin cancer.
Clients: currently, we have 5 clients. - Our business specialized in developing diagnostics and therapeutics for human basal cell carcinoma, squamous cell carcinoma, and melanoma. This skin cancer group comprises the most diagnosed cancers worldwide of all cancer types with over five million cases diagnosed each year. - The skin cancer therapeutics diagnostics and therapeutics products industry worldwide were worth $8.2 billion USD in 2019 and is projected to reach $15 billion by 2027. This represents a CAGR of 7.5%. - What share of the total skin cancer target market is realistic for us to obtain? A conservative estimate is that our company should be able to reach $200 million USD in annual revenues by the close of 2028. Problem or Need: - The main project involves the development of a Skin Cancer Patient Data Blockchain. - Currently there is a serious problem concerning how oncology patients organize and share their medical data, how companies get access to this data, and a lack of return in value to the patients for sharing their personal data. The blockchain is designed to tackle and solve these problems. - The blockchain for skin cancer patients will be comprised of multiple decentralized nodes contributing data to a shared ledger where patients can set up smart contracts to share and control their data. - Skin cancer patients will be able to share their data with research institutions, drug companies, diagnostic companies, contract research organizations, client trials organizers, and other stakeholders. - Also, planning to launch a medium of exchange within the blockchain system to allow patients to be given money for participation in the sharing of their data with the mentioned company stakeholders. - Therefore, the company stakeholders that plan to utilize the patient’s data would provide revenues and income to support the operations of the blockchain. - For example, pharmaceutical companies would be important customers that the business would cultivate as users of the patient’s healthcare data. This is because pharma companies can use this blockchain to discover patients with the right profile for a skin cancer clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. This should greatly streamline for the pharma company the time it takes to enroll the right patients into clinical trials and get them started. Value Proposition: Solution: - What is the core value proposition? For the company stakeholders in the skin cancer patient blockchain, the business is hoping to demonstrate that this blockchain technology will be a way to improve business outcomes through better efficiency, risk management, and security. - For these customers, this will enable them to maintain and capture new sources of profit. At the same time, company stakeholder participation will also grow the business as the integrator and host of the blockchain and result in significant profit growth for the company. Team: The team is comprised of: - Founder, President, and CEO, a 100% full-time permanent employee has a Ph. D. in Cell and Molecular Biology from St. John’s University (New York, NY), a M. S. in Microbiology & Immunology from Long Island University, and a M. B. A. from Le Moyne College. In addition, he has 20 years of quality assurance and regulatory affairs experience at the Bristol-Myers Squibb Company, Charles Rivers Laboratories, and Vybion, Inc. This includes moving numerous human therapeutic products from R&D, through clinical trials, and into the marketplace via approval by the US FDA and worldwide regulatory bodies. In addition to the above experience, Joseph has an addition 18 year of experience in human therapeutics research and development and in the management of laboratory-based cell culture, toxicological, or bioassay projects within the biopharmaceuticals industry. He is also a Senior Member of the food, drugs & cosmetics section of the American Society for Quality (ASQ), and a society member of The American Association for the Advancement of Science (AAAS). - The President of Hillberg Consulting is a part-time, non-permanent hourly contract employee of R&D department. She is an accomplished executive and board member with a reputation for delivering bottom-line profitability while building the infrastructure to support growth and success. She has served at Johnson & Johnson Ortho Clinical Diagnostics as VP of R&D, and as Chief Technology Officer at Carestream Health. Holly has a B. S. in Chemical Engineering from Michigan Technology University and a M. S. in Electrical Engineering from Rochester Institute of Technology. - Marketing Consultant - part-time, non-permanent hourly employee. He is a professional engineer and entrepreneurial executive with a focus on emerging technology solutions applied to real world problems. He has substantial experience in team building and in developing market strategies & partnerships. This includes over two decades of technology & networks business planning, development, & implementation. He has a Masters in Entrepreneurial Studies - MIT Sloan School of Management, and M. S. & B. S. in Engineering from Syracuse U. and Utica College. - Blockchain Development Technical Project Management Consultant - Part-time, non-permanent hourly employee that is a contractor from EffectiveSoft Corporation, San Diego, CA. She has eight years of experience as VP of Service Delivery and as the Head of Sales for enterprise level software solutions at Effective Soft Corp. She has a M. B. A. from The University of Manchester and a B. S. degree from Minsk State Linguistics U. – Legal Counsel - Part-time, non-permanent hourly contract employee. He holds the Juris Doctor from Boston College Law School, and B. A. in Political Science from Binghamton University. He is a Partner at Newman & Lickstein, with eight years of experience in representing technology companies and investors in licensing, IP development, real estate, mergers & acquisitions, and business litigation. -Medical Advisor - He is a board-certified dermatologist and fellowship-trained dermatologic surgeon from Northwestern University in Chicago that also has conducted translational research on skin, melanocytes, and photobiology, and the effects of natural compounds on skin. - Demonstrating results to stakeholders will be the key to success. For skin cancer, there is a lot of data collected from various heterogeneous sources – pathology imaging data, genetic testing, surgery, drugs intervention, payer, and insurance information, etc. - Some companies are using a website or app to meet the social needs of patients to discuss their concerns with other patients or a few qualified physicians. No competitor is comprehensively focusing on skin cancer data & treatment to the level that we do. Possible competitors have thus not yet integrated the patient data, shared consent, and the patient monetization blocks together into a comprehensive and workable blockchain system for skin cancer patients, or for any segment of the oncology market, for that matter. - This team, on the other hand, has decades of experience in oncology research, the development of products and services for cancer patients, in oncology clinical biomedicine and in oncology marketing, and that makes the company well-equipped to solve the problems around skin cancer patient data acquisition, its organization, and its beneficial use for the patients and for their healthcare providers. For example, regarding the latter, the company also harnesses artificial intelligence (AI) and machine learning (ML) to extract relevant data from the patient’s database that will help healthcare providers to better understand the patient’s tumor and the tumor microenvironment (i. e. , tumor growth, cellular migration, blood supply to the tumor, subcellular trafficking, and tumor metastasis), drug efficacy (including drug penetration into the tumor, possible tumor shrinkage or tumor death, and drug toxicity, and side effects), or the immediate or long term results of surgical intervention. - When competitors enter this specific market, the business plans to stand out by utilizing a value-based strategy that clearly displays our brand and the above competitive advantage. • Traction: - Currently works with pharmaceutical and diagnostic companies, research institutes, and contract research development and manufacturing companies to help them obtain and organize their molecular bioassays and pathology data. We propose to utilize this traction and intercompany personal connections to gain and grow customers that will use and pay for patient data on the blockchain. - Also use social media & patient advocacy organization to recommend the blockchain to skin cancer patients so that we can grow the patient database. - The company is also a member of the Hyperledger Foundation Healthcare Special Interest Group. Hyperledger, as part of the Linux Foundation, provides technology leaders with a uniquely open and collaborative international community from which to develop, validate, and field enterprise-grade blockchain technology solutions. It is the mandate of the Hyperledger Healthcare Special Interest Group (HC-SIG) to represent healthcare professionals and technologists, to globally unite these individuals, and to advance the state of the healthcare industry through the implementation of technology solutions using blockchain technologies in general, and the umbrella of Hyperledger frameworks and toolsets specifically. • Revenue Model: - Within the ecosystem surrounding the above patients, who would buy/lease the skin cancer blockchain services that the company wishes to market? In this blockchain system, individuals will be allowed to store and monetize their own health data including blood test results, medical history, genetic profile, skin photographs, pathology images and other sensitive information. - In the healthcare marketplace, cancer patients would be paid in stablecoin currency to lease their individual data to companies for a certain amount of time. - Pharmaceutical (pharma) companies would be important customers that the company would cultivate as users of the patient’s permitted healthcare data. - Blockchain can help pharma companies discover patients with the right profile for a clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. - According to Milind Kamkolkar, chief data officer at Sanofi, patients could be prompted based on their data to join a clinical trial, thereby also accelerating the process and accuracy of trial recruitment. Using this blockchain if a person declines, no personal information will be shared, and the person's identity will remain private. If the person agrees, the overall process will move faster by abolishing the need for intermediaries. - For pharma companies, better inclusion in clinical trials and better reproducibility for studies can reduce the time and money needed to develop new drugs. - Besides pharma companies, research institutes will be willing to pay for the data from skin cancer patients, and the introduction of our blockchain-based data ecosystem may help ensure that the individuals take control over their data and companies and research institutions may acquire data more freely after the latter have obtained consent from individual patients. - How are the products and services going to generate revenue? The most straightforward way to generate revenue is to have the blockchain client customers pay for the products and services that exceed by a large margin what it costs to develop and operate the blockchain (a cost-plus strategy). - When competitors enter this specific market, plan to stand out by utilizing a value-based strategy that clearly displays the brand and competitive advantage. • Market Projections: - What share of the total skin cancer blockchain target market can we estimate is realistic for to obtain? The global skin cancer blockchain customer market size stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. A conservative estimate is that the company should be able to reach $150 million in annual revenues in 4 years. - These financial projections would be possible because of the company participating and partnering with individuals and companies within the oncology community to create superior value for the products and services. - Over the next 4 years, the company anticipates receiving funding from investors, and revenues from pharmaceutical companies and research institute customers. - However, expenditure are also expected to increase. Expenses incurred will be for the development of products and services, and for personnel, equipment, supplies, business development & marketing. • Competition: - We have identified Nebula Genomics and Longenesis as competitors. These two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data. - Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical genetics data. - Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data. - The above companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. To automate data acquisition, the project developed by both Nebula Genomics and Longenesis will utilize smart contracts. - Unlike the Nebula Genomics and Longenesis blockchains, this blockchain project will be focused on oncology patients and the ecosystem around them rather than on a multitude of disease sectors. - In addition to Nebula Genomics and Longenesis, the U. S. -based life science research marketplace, Scientist. com, has revealed the development of a pharmaceuticals blockchain platform. This latter blockchain-powered platform is reportedly designed to track and protect pharmaceutical data. Thus, the Scientist. com DataSmart TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered before submission to regulators such as the FDA and the EMEA. - However, the above platforms do not adequately address the pressing concerns of cancer patients regarding the control and sharing of their personal data. Competitive Advantage: • Strategy. Specifically for oncology blockchain products, the major company players that may join our blockchain to gain access to data from skin cancer patients include: Almirall S. A. Amgen, Inc. Boehringer Ingelheim GmbH. Bristol-Myers Squibb Company. Eli Lilly and Company. Elekta AB. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc. Merck & Co. , Inc. Mylan NV. Novartis AG. Pfizer. Regeneron. Sanofi. Sun Pharmaceutical Industries Ltd. Varian Medical Systems, Inc. Sensus Healthcare. ICAD, Inc. Accuray, Inc.
We develop diagnostics, therapeutics, & digital health products and services for skin cancer.
9.2   Manlius
Run Rate Sales
USD 26 thousand
EBITDA Margin
35 %
Partial Stake Sale
USD 1 Mn for 25%
Contact Business

Bio Diagnostics Company Investment Opportunity in Phoenix, United States

Gene therapy and biomarker/diagnostic company focused on neurological conditions including; ALS, Parkinson's, Alzheimer's and TBI.
Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI. - Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells. - Has patented and licensed technologies from premier research institutions. - The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception. - The company is currently engaged in a gene therapy research project involving 2,600 samples. - There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.
7.7   Phoenix
Run Rate Sales
USD 150 thousand
EBITDA Margin
Nil
Partial Stake Sale
USD 20 Mn for 20%
Contact Business

Bio Therapeutic Drugs Company Investment Opportunity in Navi Mumbai, India

Seeking Investment: US FDA approved R&D company with 5+ pharma clients in Europe.
We do the R&D for big pharma companies. - Innovative formulation development with a focus on quality-by-design principles for precise and effective therapeutic solutions. - Commitment to excellence reflected in crafting products that redefine healthcare standards. - Fusion of innovation and precision, guided by scientific rigor, transforming pharmaceutical science into life-changing solutions. - Expertise in product development, CDMO, CMO, and TT services for five major clients, including big pharma companies. - Promoters bring 15 years of experience in R&D and product development. - Client base includes European companies, demonstrating international reach. - Regulatory approvals from the FDA and ISO 17025 underscore the company's commitment to quality and compliance. - Adaptive workforce with contract workers based on demand. - High growth attributed to the acquisition of new clients, showcasing the company's expanding market presence.
6.5   Navi Mumbai
Run Rate Sales
USD 710 thousand
EBITDA Margin
40 %
Partial Stake Sale
USD 1.18 Mn for 10%
Contact Business

Bio Therapeutic Drugs Company Investment Opportunity in Sydney, Australia

Biotech with a novel recombinant protein injection to cure back pain seeking seed investment.
Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing. - Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process. - A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions. - Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine. - Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept. - Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc. - Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients. - Positioned in the $300 billion back pain industry, addressing a significant market need. - Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development. - Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility. - Founded by individuals with decades of experience in the industry.
7.8   Sydney
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 10 Mn for 35%
Contact Business

Bio Diagnostics Company Investment Opportunity in Uxbridge, United Kingdom

Invest in the UK healthcare business for potential growth in the gene therapy field.
• Healthcare business located in the United Kingdom offering gene therapy products and services. • University spin-out with patented technology and other scientific developments in the pipeline. • Aiming to improve the safety and efficiency of gene therapy. • Top selling products will be tests to ascertain if a person can repair their DNA, testing if a virus used to deliver a gene therapy will actually be safe. • Gene therapy and CAR-T therapy is a rapidly growing field, offering great potential for the company. • Experienced team of scientists and engineers ready to create a successful business. The business is not operational currently. • Unique products and services that can be marketed to potential customers worldwide.
7.4   Uxbridge
Run Rate Sales
Nil
EBITDA Margin
Nil
Partial Stake Sale
USD 650 K for 25%
Contact Business
Frequently
Asked
Questions
  • How many biotechnology business investment opportunities are listed on SMERGERS?
    There are 30 active and verified biotechnology business investment opportunities listed on SMERGERS as of 05 December 2024.
  • What level of due diligence does SMERGERS conduct on the businesses/member?

    SMERGERS scrutinizes all profiles and only features a select group of businesses, investors, advisors that meet a basic requirement. When required, certain members may have submitted some form of proof …read more

  • How active are the business profiles listed on SMERGERS?

    We regularly filter out businesses which are inactive or have already closed a transaction. Typically, if the business is actively looking to sell/raise capital, the status is shown in green.

  • How can I be sure about privacy and confidentiality?

    We understand the level of confidentiality required in strategic transactions and we strive to provide a safe and secure experience for our members. Please review our privacy policy. We …read more

  • How can I contact a business listed on SMERGERS?

    You need to be logged in before you connect with a business. Click here to register and message the business If you are already logged in, please use the contact …read more

  • Should you buy an existing business or start a business from scratch?

    Buying an existing business is generally an easier way to start a business with an immediate head start. It saves valuable time and administrative efforts, considering starting from scratch is …read more

  • How successful has SMERGERS been in helping its users successfully close a deal?

    SMERGERS is a discovery and matchmaking platform with a global reach. It helps in connecting Businesses, Investors, Acquirers, Lenders, M&A Advisors and Boutique Investment Banks across locations, industries and transactions. …read more

  • Show more